Skip to main content
. Author manuscript; available in PMC: 2018 Jul 25.
Published in final edited form as: J Am Coll Surg. 2016 Nov;223(5):717–728.e4. doi: 10.1016/j.jamcollsurg.2016.08.541

Table 1.

Baseline characteristics.

Borderline
lumpectomy-
eligible
patients
Locally-
advanced
patients
P-value Total
N (%)
IIA (T2N0),
IIB, IIIA
(T3N1)
N (%)
IIIA (T0-
3N2), IIIB,
IIIC
N (%)
Age (years) .0003
  <50 44,824 (46) 9,289 (45) 54,113 (46)
  50–54 19,150 (20) 4,078 (20) 23,228 (20)
  55–59 17,676 (18) 4,009 (19) 21,685 (18)
  60–64 15,716 (16) 3,344 (16) 19,060 (16)
Race** <.0001
  White non-Hispanic 66,293 (73) 13,135 (68) 79,428 (72)
  Black non-Hispanic 13,681 (15) 3,726 (19) 17,407 (16)
  Hispanic 6,884 (8) 1,721 (9) 8,605 (8)
  Other 4,570 (5) 795 (4) 5,365 (5)
Insurance status <.0001
  Private 78,113 (80) 14,914 (72) 93,027 (79)
  Medicaid 12,205 (13) 3,828 (19) 16,033 (14)
  Other government 1,361 (1) 284 (1) 1,645 (1)
  None or unknown 5,687 (6) 1,694 (8) 7,381 (6)
Year of Diagnosis <.0001
  2006 7,359 (8) 2,185 (11) 9,544 (8)
  2007 8,968 (9) 2,516 (12) 11,484 (10)
  2008 13,345 (14) 3,198 (15) 16,543 (14)
  2009 15,222 (16) 3,178 (15) 18,400 (16)
  2010 17,188 (18) 3,420 (17) 20,608 (18)
  2011 17,769 (18) 3,232 (16) 21,001 (18)
  2012 17,515 (18) 2,991 (14) 20,506 (17)
Charlson/Deyo Comorbidity Score .09
  0 86,755 (89) 18,369 (89) 105,124 (89)
  1 9,260 (10) 2,031 (10) 11,291 (10)
  2+ 1,351 (1) 320 (2) 1,671 (1)
Facility location* <.0001
  South 37,203 (38) 8,416 (41) 45,619 (39)
  Midwest 26,188 (27) 5,313 (26) 31,501 (27)
  Northeast 17,048 (18) 3,634 (18) 20,682 (18)
  West 16,927 (17) 3,357 (16) 20,284 (17)
Facility type <.0001
  Academic/research 32,501 (33) 6,867 (33) 39,368 (33)
  Comprehensive community cancer program 55,206 (57) 11,448 (55) 66,654 (56)
  Community cancer program 9,659 (10) 2,405 (12) 12,064 (10)
Population density .04
  Non-rural 92,698 (98) 19,646 (98) 112,344 (98)
  Rural 1,517 (2) 362 (2) 1,879 (2)
Tumor grade <.0001
  1 8,457 (9) 952 (5) 9,409 (8)
  2 34,790 (38) 6,303 (33) 41,093 (37)
  3+ 49,316 (53) 11,808 (62) 61,124 (55)
HR Summary (Years 2006–2009) <.0001
  ER+ or PR+ 13,859 (32) 4,076 (38) 36,858 (67)
  ER and PR− or borderline 30,134 (69) 6,724 (62) 17,935 (33)
HR/HER2 summary (Years 2010–2012) <.0001
  HR+/HER2− 29,420 (60) 4,473 (49) 33,893 (58)
  HR+/HER2+ 6,618 (13) 1,464 (16) 8,082 (14)
  HR−/HER2+ 3,281 (7) 1,081 (12) 4,362 (8)
  HR−/HER2− 10,045 (20) 2,061 (23) 12,106 (21)
AJCC Clinical Stage ---
  IIA (T2N0 only) 58,781 (60) - 58,781 (50)
  IIB 30,636 (32) - 30,636 (26)
  IIIA (T3N1 only) 7,949 (8) - 7,949 (7)
  IIIA (T0-3N2 only) - 8,024 (39) 8,024 (7)
  IIIB non-inflammatory - 4,884 (24) 4,884 (4)
  IIIC non-inflammatory - 4,221 (20) 4,221 (4)
  Inflammatory (T4d) - 3,591 (17) 3,591 (3)
Histology
  Invasive ductal carcinoma 82,992 (85) 17,030 (82) <.0001 100,022 (85)
  Invasive lobular carcinoma 9,101 (9) 1,457 (7) 10,558 (9)
  Mixed ductal and lobular 5,229 (5) 944 (5) 6,173 (5)
  Inflammatory 44 (<1) 1,289 (6) 1,333 (1)
Laterality <.0001
  Unilateral 97,331 (>99) 20,697 (>99) 118,028 (>99)
  Bilateral 35 (<1) 23 (<1) 58 (<1)

Abbreviations: AJCC, American Joint Committee on Cancer. HR, Hormone Receptor. HER2, Human Epidermal Growth Factor Receptor 2.

**

Approximately 6% of patients had missing information on race.

*

South includes Washington DC, Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas; Midwest includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, North Dakota, Nebraska, South Dakota; Northeast includes Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania; West includes Arizona, Colorado, Idaho, Montana, New Mexico, Nevada, Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.